Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Cells. 2022 Jun 17;11(12):1960. doi: 10.3390/cells11121960.
Tumor-infiltrating CD45RO+ memory T cells have unanimously been described as a positive prognostic factor in head and neck squamous cell carcinomas (HNSCCs). Here, we investigated the long-term prognostic relevance of CD45RO+ memory T cells in HNSCC with special regard to the influence of clinical characteristics. Pre-treatment biopsy samples from 306 patients with predominantly advanced HNSCC were analyzed. Immunohistochemistry was used to stain tissue microarrays for CD45RO+ memory T cells. CD45RO cell densities were semi-automatically registered and used for survival analysis. High CD45RO+ cell densities were clearly associated with prolonged overall survival (OS) and recurrence-free survival as well as no evidence of disease status after 10 years (p < 0.05). In contrast, the prognostic significance of tumor-infiltrating memory T cells was completely reversed in high-risk groups: in poorly differentiated tumors (G3, G4) and in cases with lymph node involvement (N+), high memory T cell densities correlated with reduced 10-year OS (p < 0.05). In conclusion, an increased density of tumor-infiltrating CD45RO+ cells in HNSCC can be a positive as well as a negative prognostic factor, depending on disease stage and histological grade. Therefore, if CD45RO+ cell density is to be used as a prognostic biomarker, further clinical characteristics must be considered.
肿瘤浸润性 CD45RO+记忆 T 细胞一致被描述为头颈部鳞状细胞癌(HNSCC)的一个阳性预后因素。在这里,我们研究了 CD45RO+记忆 T 细胞在 HNSCC 中的长期预后相关性,特别关注了临床特征的影响。分析了 306 例主要为晚期 HNSCC 患者的预处理活检样本。免疫组织化学用于染色组织微阵列以检测 CD45RO+记忆 T 细胞。半自动记录 CD45RO 细胞密度,并用于生存分析。高 CD45RO+细胞密度与延长的总生存期(OS)和无病生存期以及 10 年后无疾病状态明显相关(p<0.05)。相比之下,在高危组中,肿瘤浸润性记忆 T 细胞的预后意义完全相反:在低分化肿瘤(G3、G4)和淋巴结受累(N+)的情况下,高记忆 T 细胞密度与降低的 10 年 OS 相关(p<0.05)。总之,HNSCC 中肿瘤浸润性 CD45RO+细胞密度的增加既可以是一个阳性预后因素,也可以是一个阴性预后因素,具体取决于疾病分期和组织学分级。因此,如果要将 CD45RO+细胞密度用作预后生物标志物,则必须考虑其他临床特征。